Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders.
First prefab biologics plant goes up in China, in 11 days. JHL Biotech intends to manufacture biosimilars in its new facility.
(GenomeWeb) – Strand Life Sciences is aiming to position its 152-gene cancer sequencing test for solid tumors as a tool that can be used early on in a patient's disease in order to inform first-line therapy.
JHL Biotech (TWEM: 6540), an emerging biosimilars company incorporated in Cayman Islands and based in Taiwan and China, announced today it has been publicly listed on the Taiwan Emerging Stock Board, effective September 17, 2015.
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for RI-002 intended for the primary immunodeficiency (PI) population.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
Juno Therapeutics, Inc. today announced the pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share. In addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any. Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “JUNO” on December 19, 2014. The offering is expected to close on December 23, 2014, subject to customary closing conditions.
Opus Bio, Inc., today announced that Juno Therapeutics, Inc. has entered into an agreement to obtain a license for the company’s CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas.
ADMA Biologics, Inc. (Nasdaq:ADMA) today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.
ADMA Biologics, Inc. (OTCQB:ADMA) today announced that the NASDAQ stock market has approved ADMA's common stock for listing on the NASDAQ Capital Market and is expected to begin trading on November 10, 2014 under the symbol "ADMA."
Alcon, the global leader in eye care and the second largest division of Novartis Group, announced today that the company has entered into an agreement to acquire WaveTec Vision.
Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc.
Strand Life Sciences Pvt. Ltd. and Health Care Global Enterprises Ltd. are proud to announce the launch of The Strand Triesta Center For Cancer Genomics at a symposium on Clinical Genomics: New Generation Cancer Care.
HealthCare Global (HCG) Enterprises Ltd, The Specialists in Cancer Care, creates a new benchmark in cancer care by making genomics-based diagnostics, a ‘standard-of-care’ for cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for “actionable” mutations. The information about these mutations helps to identify targeted therapies and treatment choices early in the course of cancer care.
Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activity, and Strand Scientific Intelligence, Inc. (Strand) announce the launch of the Curie Image Database (CID), a breakthrough image analysis and management platform that they developed jointly over the last two years at the Cell and Tissue Imaging Core Facility of the Institut Curie (PICT-IBiSA).
Strand Life Sciences Private Limited, a global life sciences company headquartered in Bangalore, is collaborating with the San Francisco Bay Area based El Camino Hospital to locate a Strand Center for Genomics and Personalized Medicine at the Genomic Medicine Institute of the El Camino Hospital to accelerate the adoption of next generation sequencing based research panels and counseling services by the physicians at the Hospital and its partner clinics.
Strand Life Sciences, a bioinformatics company whose products for Array, Mass Spec and NGS analysis are used by over 2000 laboratories worldwide and has recently developed solutions in the field of clinical diagnostics, is launching its Early Access Program for its clinical genomics interpretation and reporting platform. Strand’s clinical application is a deep interpretation and reporting system for clinical genomics. It was designed in collaboration with clinicians while working on real patient cases in Strand’s clinical laboratory, and therefore provides the necessary information to help medical practitioners confidently deliver clinical reports with ease.
Strand Life Sciences, a bioinformatics company whose products for Array, Mass Spec and NGS analysis are used by over 2000 laboratories worldwide and has recently developed solutions in the field of clinical diagnostics, is launching its Early Access Program for its clinical genomics interpretation and reporting platform. Strand’s clinical application is a deep interpretation and reporting system for clinical genomics. It was designed in collaboration with clinicians while working on real patient cases in Strand’s clinical laboratory, and therefore provides the necessary information to help medical practitioners confidently deliver clinical reports with ease. “Strand is combining its clinical laboratory experience with its formidable computational expertise to build an application that accelerates clinical genomics interpretation and reporting,” said Dr. Vijay Chandru, CEO of Strand, “and we are excited to launch our Early Access Program to make this platform accessible to other labs who could benefit from its use.”
On BetterDoctor, which functions like an “Opentable for doctors,” you can search for a health care expert in a range of specialties. Its database features one million doctors and other care providers, located in various cities around the country. Most of these doctors have never heard of BetterDoctor. The startup’s team of programmers have scraped Yelp, hospital listings, private practice sites, and the like to create custom profiles for doctors with reviews and location information. Many of these doctors will only hear about BetterDoctor, after they experience a spike in patient requests and foot traffic.
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the pricing of its initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. All of the shares of common stock are being offered by ADMA Biologics. In addition, ADMA Biologics has granted the underwriters a 30-day option to purchase up to an additional 502,941 shares of common stock at the same price to cover over-allotments, if any. The company's shares are expected to begin trading on The OTCQB Marketplace on October 17, 2013 under the ticker symbol “ADMA.”